Search Results - "Goodman, Andrew D"

Siponimod in the treatment of multiple sclerosis by Goodman, Andrew D, Anadani, Nidhiben, Gerwitz, Lee

“…: Multiple sclerosis (MS) causes focal lesions of immune-mediated demyelinating events followed by slow progressive accumulation of disability. Over the past 2…”
Get more information

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial by Goodman, Andrew D, Prof, Brown, Theodore R, MD, Krupp, Lauren B, MD, Schapiro, Randall T, MD, Schwid, Steven R, MD, Cohen, Ron, MD, Marinucci, Lawrence N, MS, Blight, Andrew R, PhD

“…Summary Background Clinical studies suggested that fampridine (4-aminopyridine) improves motor function in people with multiple sclerosis. This phase III study…”
Get full text

Unemployment in multiple sclerosis: the contribution of personality and disease by Strober, Lauren B, Christodoulou, Christopher, Benedict, Ralph HB, Westervelt, Holly J, Melville, Patricia, Scherl, William F, Weinstock-Guttman, Bianca, Rizvi, Syed, Goodman, Andrew D, Krupp, Lauren B

“…Background: Multiple sclerosis (MS) is the leading cause of neurological disability among young and middle-aged adults. One of the most devastating…”
Get full text

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients by Rudick, Richard A., O'Connor, Paul W., Polman, Chris H., Goodman, Andrew D., Ray, Soma S., Griffith, Nancy M., Jurgensen, Stephanie A., Gorelik, Leonid, Forrestal, Fiona, Sandrock, Alfred W., E. Goelz, Susan

“…Objective Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab‐treated multiple sclerosis…”
Get full text

Symptomatic Management in Multiple Sclerosis by Samkoff, Lawrence M., MD, Goodman, Andrew D., MD

“…The development of immunomodulatory therapies for multiple sclerosis (MS) has had significant impact in altering the natural history of the disease. Although…”
Get full text

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial by Applebee, Angela, MD, Goodman, Andrew D., MD, Mayadev, Angeli S., MD, Bethoux, Francois, MD, Goldman, Myla D., MD, MSc, Klingler, Michael, MPH, Blight, Andrew R., PhD, Carrazana, Enrique J., MD

“…Abstract Purpose Dalfampridine extended-release (ER) tablets 10 mg BID have been approved for use in improving walking in people with multiple sclerosis (MS)…”
Get full text

Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases by Levin, Seth N., Venkatesh, Shruthi, Nelson, Katie E., Li, Yi, Aguerre, Ines, Zhu, Wen, Masown, Karman, Rimmer, Kathryn T., Diaconu, Claudiu I., Onomichi, Kaho B., Leavitt, Victoria M., Levine, Libby L., Strauss‐Farber, Rebecca, Vargas, Wendy S., Banwell, Brenda, Bar‐Or, Amit, Berger, Joseph R., Goodman, Andrew D., Longbrake, Erin E., Oh, Jiwon, Weinstock‐Guttman, Bianca, Thakur, Kiran T., Edwards, Keith R., Riley, Claire S., Xia, Zongqi, De Jager, Philip L.

“…Objective To report initial results of a planned multicenter year‐long prospective study examining the risk and impact of COVID‐19 among persons with…”
Get full text

Defining the clinical course of multiple sclerosis: The 2013 revisions by Lublin, Fred D, Reingold, Stephen C, Cohen, Jeffrey A, Cutter, Gary R, Sørensen, Per Soelberg, Thompson, Alan J, Wolinsky, Jerry S, Balcer, Laura J, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Calabresi, Peter A, Clanet, Michel, Comi, Giancarlo, Fox, Robert J, Freedman, Mark S, Goodman, Andrew D, Inglese, Matilde, Kappos, Ludwig, Kieseier, Bernd C, Lincoln, John A, Lubetzki, Catherine, Miller, Aaron E, Montalban, Xavier, OʼConnor, Paul W, Petkau, John, Pozzilli, Carlo, Rudick, Richard A, Sormani, Maria Pia, Stüve, Olaf, Waubant, Emmanuelle, Polman, Chris H

“…Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of…”
Get full text

Comparison of telemedicine versus in-person visits for persons with multiple sclerosis: A randomized crossover study of feasibility, cost, and satisfaction by Robb, Jessica F, Hyland, Megan H, Goodman, Andrew D

“…•Virtual house calls were found to be feasible for MS patient follow-up visits.•Virtual house calls for MS patients had high participant…”
Get full text

Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium by Jakimovski, Dejan, Kavak, Katelyn S., Coyle, Patricia K., Goodman, Andrew D., Gottesman, Malcolm, Zivadinov, Robert, Weinstock-Guttman, Bianca

“…Background The impact of disease-modifying treatments (DMTs) on multiple sclerosis (MS) long-term outcomes is continuously evolving. Retrospective analyses of…”
Get full text

Cognitive fatigue during a test requiring sustained attention: a pilot study by Schwid, Steven R, Tyler, Carolyn M, Scheid, Eileen A, Weinstein, Amy, Goodman, Andrew D, McDermott, Michael P

“…Background: Fatigue is common in multiple sclerosis (MS), but difficulty quantifying fatigue severity has impeded studies of its characteristics, mechanisms,…”
Get full text

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis by Goodman, Andrew D., Brown, Theodore R., Edwards, Keith R., Krupp, Lauren B., Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N., Blight, Andrew R.

“…Objective A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended‐release…”
Get full text

Fingolimod-associated PML in a patient with prior immunosuppression by Gyang, Tirisham V, Hamel, Johanna, Goodman, Andrew D, Gross, Robert A, Samkoff, Lawrence

“…Fingolimod, a sphingosine-1-phosphate receptor modulator, was the first oral disease-modifying drug approved for relapsing-remitting multiple sclerosis (RRMS)…”
Get full text

Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis by Fox, Robert J, Raska, Paola, Barro, Christian, Karafa, Matthew, Konig, Victoria, Bermel, Robert A, Chase, Marianne, Coffey, Christopher S, Goodman, Andrew D, Klawiter, Eric C, Naismith, Robert T, Kuhle, Jens

“…Background: Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light…”
Get full text

Enhancing Neural Transmission in Multiple Sclerosis (4-Aminopyridine Therapy) by Goodman, Andrew D., Stone, Robert Thompson

“…Enhancing neural transmission by improving axonal conduction and synaptic neurotransmitter release is a novel strategy to improve symptoms in multiple…”
Get full text

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine by Hobart, Jeremy, Ziemssen, Tjalf, Feys, Peter, Linnebank, Michael, Goodman, Andrew D., Farrell, Rachel, Hupperts, Raymond, Blight, Andrew R., Englishby, Veronica, McNeill, Manjit, Chang, Ih, Lima, Gabriel, Elkins, Jacob

“…Background Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively…”
Get full text

Ibudilast for the treatment of multiple sclerosis by Goodman, Andrew D, Gyang, Tirisham, Smith, 3rd, Andrew D

“…Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) characterized by inflammatory demyelination and progressive axonal loss…”
Get more information

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis by Cohen, Jeffrey A, Krishnan, Arun V, Goodman, Andrew D, Potts, James, Wang, Ping, Havrdova, Eva, Polman, Chris, Rudick, Richard A

“…Walking impairment, a common clinical manifestation of multiple sclerosis (MS), is often measured in clinical practice and clinical trials using the Timed…”
Get more information

Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis by Bermel, Robert A, Fedler, Janel K, Kaiser, Peter, Novalis, Cindy, Schneebaum, Jeff, Klingner, Elizabeth A, Williams, Dawn, Yankey, Jon W, Ecklund, Dixie J, Chase, Marianne, Naismith, Robert T, Klawiter, Eric C, Goodman, Andrew D, Coffey, Christopher S, Fox, Robert J

“…Background: The SPRINT-MS trial demonstrated benefit of ibudilast on brain atrophy over 96 weeks in progressive multiple sclerosis (MS). Optical coherence…”
Get full text

A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment by Cohen, Jeffrey A, Cameron, Michelle H, Goldman, Myla D, Goodman, Andrew D, Miller, Aaron E, Rollins, Anne, Llorens, Lily, Patni, Rajiv, Elfont, Robert, Johnson, Reed

“…Background: ADS-5102, a delayed-release, extended-release (DR/ER) amantadine, improved walking speed in MS in a Phase 2 trial. Objective: The aim of this study…”
Get full text